Topical Cenegermin-Bkbj Dramatically Resolves Neurotrophic Keratitis Associated With Pars Plana Vitrectomy

Area of Science:

• Ophthalmology
• Regenerative Medicine

Background:

• Neurotrophic keratitis (NK) is a potential complication following pars plana vitrectomy (PPV).
• Severe NK may necessitate advanced treatment strategies.
• Cenegermin-Bkbj, a recombinant human nerve growth factor, offers a novel therapeutic approach.

Purpose of the Study:

• To present a case of refractory iatrogenic NK post-vitrectomy successfully treated with Cenegermin-Bkbj.
• To highlight the efficacy of Cenegermin-Bkbj in severe cases unresponsive to conventional therapy.

Main Methods:

• A 60-year-old female patient with severe iatrogenic NK post-multiple PPV surgeries was treated.
• Daily topical Cenegermin-Bkbj was administered for 8 weeks.
• Treatment outcomes were assessed by corneal reepithelialization, sensation, and visual acuity.

Main Results:

• Complete corneal reepithelialization was achieved.
• Corneal sensation and visual acuity improved from hand motion to 20/80.
• The patient remained symptom-free at 8-week follow-up.

Conclusions:

• Cenegermin-Bkbj demonstrates potential efficacy in treating refractory neurotrophic keratitis following retinal procedures.
• Early recognition and tailored management are crucial for optimal outcomes in post-vitrectomy NK.
• This case supports Cenegermin-Bkbj as a viable option for severe iatrogenic NK.